http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2022025104-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-22 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-60 |
| filingDate | 2021-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2022025104-A |
| titleOfInvention | CNP prodrug with carrier binding in the ring moiety |
| abstract | PROBLEM TO BE SOLVED: To provide a safer and more accessible type C natriuretic peptide (CNP) having a low risk of hypotension. SOLUTION: A carrier moiety-Z attached to a reversible prodrug linker moiety-L 1- via a CNP moiety-D including a ring moiety and a moiety-L 2- , wherein the reversible prodrug. The drug linker moiety -L 1- is covalently and reversibly bound to the side chain of the amino acid residue of the ring moiety of -D or to the skeleton of the ring moiety of -D. , Chemical bonds or spacers, CNP prodrugs or pharmaceutically acceptable salts of the prodrugs are used. [Selection diagram] Fig. 1 |
| priorityDate | 2016-01-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 44.